Martin C. Gregory
No Rating Available
(Learn About Our Rating System)

Martin C. Gregory, DPhil, MBChB

Languages spoken: English, French

Clinical Locations

Primary Location

University of Utah Hospital

Nephrology
50 N Medical Dr
Salt Lake City , UT 84132
Get Directions

Martin Gregory, MD, PhD is a Clinical Professor of Medicine at the University of Utah School of Medicine. As a nephrologist, his clinical interests include general nephrology and hereditary renal diseases.

Dr. Gregory received his BM, BCh and DPhil Degrees (MD, PhD equivalents) from Oxford University. He received training in medicine and nephrology from the University of Otago, New Zealand, and Oxford University. He completed his residency at the University of London and at Oxford University, then fellowship in nephrology at Oxford University. He received further nephrology training at the University of Paris (VI). Dr. Gregory is board certified in Internal Medicine and Nephrology. In the past, Dr. Gregory served as Chief of Nephrology at Groote Schuur Hospital, Cape Town, South Africa and as Director of Dialysis Services, Bermuda Hospitals Board, Bermuda. He is currently a member of the Medical Advisory Board of the Alport Syndrome Foundation and a member of the Medical Advisory Board of the National Kidney Foundation of Utah and Idaho.

Specialties

Board Certification

American Board of Internal Medicine (Sub: Nephrology)
American Board of Internal Medicine (Internal Medicine)

Martin Gregory, MD, PhD is a Clinical Professor of Medicine at the University of Utah School of Medicine. As a nephrologist, his clinical interests include general nephrology and hereditary renal diseases.

Dr. Gregory received his BM, BCh and DPhil Degrees (MD, PhD equivalents) from Oxford University. He received training in medicine and nephrology from the University of Otago, New Zealand, and Oxford University. He completed his residency at the University of London and at Oxford University, then fellowship in nephrology at Oxford University. He received further nephrology training at the University of Paris (VI). Dr. Gregory is board certified in Internal Medicine and Nephrology. In the past, Dr. Gregory served as Chief of Nephrology at Groote Schuur Hospital, Cape Town, South Africa and as Director of Dialysis Services, Bermuda Hospitals Board, Bermuda. He is currently a member of the Medical Advisory Board of the Alport Syndrome Foundation and a member of the Medical Advisory Board of the National Kidney Foundation of Utah and Idaho.

Board Certification and Academic Information

Academic Departments Internal Medicine -Adjunct Professor
Academic Divisions Nephrology & Hypertension
Board Certification
American Board of Internal Medicine (Sub: Nephrology)
American Board of Internal Medicine (Internal Medicine)

Education history

Undergraduate Premedical Sciences - University of Otago B.Med.Sciences
Undergraduate University of Oxford B.A.
Professional Medical Medicine - University of Oxford M.D.
Graduate Training Physiology - University of Oxford M.A.
Internship General Medicine/Surgery - Radcliffe Infirmary Intern
Residency Internal Medicine - Hammersmith Resident
Fellowship Neph-Hypertension - Churchill Hospital Fellow
Fellowship Nephrology - Radcliffe Infirmary Fellow
Doctoral Training University of Oxford Ph.D.
Residency Nephrology - Hopital Necker Resident
Residency Neurology - Churchill Hospital Resident

Selected Publications

Journal Article

  1. Goodenough GK, Lutz LJ, Gregory MC (1988). Home-based renal dialysis. Am Fam Physician, 37(2), 203-14.
  2. Gregory MC, Schumann GB, Schumann JL, Argyle JC (1984). The clinical significance of candidal casts. Am J Kidney Dis, 4(2), 179-84.
  3. Doyle AJ, Gregory MC, Terreros DA (1994). Percutaneous native renal biopsy: comparison of a 1.2-mm spring-driven system with a traditional 2-mm hand-driven system. Am J Kidney Dis, 23(4), 498-503.
  4. Anderson CJ, Gregory MC, Groggel GC, Clegg DO (1989) (1989). Amyloidosis and Reiter's syndrome: report of a case and review of the literature. Am J Kidney Dis, 14(4), 319-23.
  5. Anderson CJ, Gregory MC, Groggel GC, Clegg DO (1989). Amyloidosis and Reiter's syndrome: report of a case and review of the literature. Am J Kidney Dis, 14(4), 319-23.
  6. Barker DF, Pruchno CJ, Jiang X, Atkin CL, Stone EM, Denison JC, Fain PR, Gregory MC (1996). A mutation causing Alport syndrome with tardive hearing loss is common in the western United States. Am J Hum Genet, 58(6), 1157-65.
  7. Heath KE, Campos-Barros A, Toren A, Rozenfeld-Granot G, Carlsson LE, Savige J, Denison JC, Gregory MC, White JG, Barker DF, Greinacher A, Epstein CJ, Glucksman MJ, Martignetti JA (2001). Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet, 69(5), 1033-45.
  8. Bichet DG, Hendy GN, Lonergan M, Arthus M-F, Ligier S, Pausova Z, Kluge R, Zingg H, Saenger P, Oppenheimer E, Hirsch DJ, Gilgenkrantz S, Salles J-P, Oberlé I, Mandel J-L, Gregory MC, Fujiwara M, Morgan K, Scriver CR (1992). X-linked nephrogenic diabetes insipidus: from the ship Hopewell to RFLP studies. Am J Hum Genet, 51, 1089-1092.
  9. Barker DF, Denison JC, Atkin CL, Gregory MC (2001). Efficient detection of Alport syndrome COL4A5 mutations with multiplex genomic PCR-SSCP. Am J Med Genet, 98(2), 148-60.
  10. Russo-Marie F, Gregory M, Ulmann A, Funck-Brentano JL (1976). [Role of sodium in the intestinal transport of calcium in idiopathic hypercalciuria] Ann Med Interne (Paris), 127(2), 113-6.
  11. Gregory MC (1984). Acute renal failure after percutaneous cholangiography. Arch Intern Med, 144(6), 1288-9.
  12. Cheung AK, DeVault GA Jr, Gregory MC (1993). A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol, 3(12), 1884-91.
  13. Martin P, Heiskari N, Zhou J, Leinonen A, Tumelius T, Hertz JM, Barker D, Gregory M, Atkin C, Styrkarsdottir U, Neumann H, Springate J, Shows T, Pettersson E, Tryggvason K (1998). High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol, 9(12), 2291-301.
  14. Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masoumi A, Schrier RW (2010). Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol, 21(5), 876-83.
  15. Cheung AK, DeVault GA, Gregory MC (1993). A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol, 31, 1884-1891.
  16. Heiskari N, Zhang X, Zhou J, Leinonen Anu, Barker D, Gregory M, Atkin C, Netzer KO, Weber M, Reeders S, Grönhagen-Riska C, Neumann H, Trembath R, Tryggvason K (1996). Identification of 17 mutations in ten exons in the COL4A5 collagen gene, but no mutations found in four exons in COL4A6: a study of 250 patients with hematuria and suspected of having Alport syndrome. J Am Soc Nephrol, 7, 702-709.
  17. Wester DC, Atkin CL, Gregory MC (1995). Alport syndrome: clinical update. J Am Acad Audiol, 6(1), 73-9.
  18. Leypoldt JK, Kablitz C, Gregory MC, Senekjian HO, Cheung AK (1991). Prescribing hemodialysis using a weekly urea balance model. Blood Purif, 9, 241-245.
  19. Zehnder AF, Adams JC, Santi PA, Kristiansen AG, Washarasindhu C, Mann S, Kalluri R, Gregory MC, Kashtan CE, Merchant SN (2005). Distribution of tiype IV collagen in the cochlea in Alport syndrome. Arch Otolaryngol Head Neck Surg, 131(11), 1007-13.
  20. Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, Rheault M, Licht C (2013). Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol, 28(1), 5-11.
  21. Baker LR, Mallinson WJ, Gregory MC, Menzies EA, Cattell WR, Whitfield HN, Hendry WF, Wickham JE, Joekes AM (1987). Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases. Br J Urol, 60(6), 497-503.
  22. Gregory MC, Micklos T, Miller FJ, Servilla KS, Nelson EW (1988). Percutaneous dilation and stenting of ureteral stenosis in renal transplantation. Clin Transplant, 2, 107-109.
  23. Parr CJ, Miller FJ, Gregory MC, Yoon HC (2004). SIR 2004 Film panel case: Primary hyperoxaluria type I mimicking arterial vasculitis--a lethal disease. J Vasc Interv Radiol, 15(9), 1017-20.
  24. Parr CJ, Miller FJ, Gregory MC, Yoon HC (2004). SIR 2004 film panel case: Primary hyperoxaluria type I mimicking arterial vasculitis--a lethal disease. J Vasc Interv Radiol, 15(9), 1017-20.
  25. Gregory, MC (2009). Cost-Effective Dialysis for the Developing World. Ethn Dis, 19(Spring), S1 65-67.
  26. Gregory MC (2009). Cost-effective dialysis for the developing world. Ethn Dis, 19(1 Suppl 1), S1-65-7.
  27. Terreros DA, Gregory MC (1988). Metabolic Bone Disease in Patients Undergoing Chronic Dialysis. Am Soc Clinical Path. Check Sample Continuing Education Program. Clin Chem, CC88-7, 1-4.
  28. Smith JB, Ash KO, Gregory MC, Sprowell WL, Hentschel WM, Williams RR (1984). Hemodialysis does not affect erythrocyte sodium-lithium countertransport. Clin Chim Acta, 143(3), 275-9.
  29. Gregory MC, Duffy DP (1983). Toxic shock following staphylococcal peritonitis. Clin Nephrol, 20(2), 101-4.
  30. New Zealand Glomerulonephritis Study Group et al (1989). The New Zealand glomerulonephritis study: introductory report. Clin Nephrol, 31(5), 239-246.
  31. Gregory MC, Duval D, Meyer P (1976). Changes in cardiac and hepatic glucocorticoid receptors after adrenalectomy. Clin Sci Mol Med, 51(5), 487-93.
  32. Gregory MC, Terreros DA, Barker DF, Fain PN, Denison JC, Atkin CL (1996). Alport syndrome--clinical phenotypes, incidence, and pathology. Contrib Nephrol, 117, 1-28.
  33. Barker DF, Atkin CL, Gregory MC, Fain PR (1996). Application of linked markers for genetic diagnosis of Alport syndrome. Contrib Nephrol, 117, 29-45.
  34. Christensen AJ, Smith TW, Turner CW, Holman JM Jr, Gregory MC (1990). Type of hemodialysis and preference for behavioral involvement: interactive effects on adherence in end-stage renal disease. Health Psychol, 9(2), 225-36.
  35. Argyle C, Schumann GB, Genack L, Gregory M (1984). Identification of fungal casts in a patient with renal candidiasis. Hum Pathol, 15(5), 480-1.
  36. Barker DF, Denison JC, Atkin CL, Gregory MC (1997). Common ancestry of three Ashkenazi-American families with Alport syndrome and COL4A5 R1677Q. Hum Genet, 99(5), 681-4.
  37. Barker DF, Fain PR, Goldgar DE, Dietz-Bank JN, Turco AE, Kashtan CE, Gregory MC, Tryggvason K, Skolnick MH, Atkin CL (1991). High density genetic and physical mapping of DNA markers near the X-linked Alport syndrome locus: Definition and use of flanking polymorphic markers. Hum Genet, 88, 189-194.
  38. Barker DF, Fain PR, Goldgar DE, Dietz-Band JN, Turco AE, Kashtan CE, Gregory MC, Tryggvason K, Skolnick MH, Atkin CL (1991). High-density genetic and physical mapping of DNA markers near the X-linked Alport syndrome locus: definition and use of flanking polymorphic markers. Hum Genet, 88(2), 189-94.
  39. Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M (1979). Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab, 48(1), 50-3.
  40. Bichet DG, Arthus MF, Lonergan M, Hendy GN, Paradis AJ, Fujiwara TM, Morgan K, Gregory MC, Rosenthal W, Didwania A (1993). X-linked nephrogenic diabetes insipidus mutations in North America and the Hopewell hypothesis. J Clin Invest, 92(3), 1262-8.
  41. Christensen AJ, Turner CW, Smiths TW, Holman JM, Gregory MC (1991). Health locus of control and depression in chronic illness; moderating effects of treatment status and illness severity. J Consult Clin Psychol, 59, 419-424.
  42. Christensen AJ, Turner CW, Smith TW, Holman JM Jr, Gregory MC (1991). Health locus of control and depression in end-stage renal disease. J Consult Clin Psychol, 59(3), 419-24.
  43. Christensen AJ, Smith TW, Turner CW, Holman JM Jr, Gregory MC, Rich MA (1992). Family support, physical impairment, and adherence in hemodialysis: an investigation of main and buffering effects. J Behav Med, 15(4), 313-25.
  44. Gregory MC, Hughes JT (1973). Intracranial reticulum cell sarcoma associated with immunoglobulin A deficiency. J Neurol Neurosurg Psychiatry, 36(5), 769-76.
  45. Giles TD, Weber M, Bartels DW, Gregory MC, Burris JF, Due D, Sirgo MA (1991). Evaluation of labetalol in elderly patients with essential hypertension. J Clin Hypertens, 31, 556-560.
  46. Taylor A Jr, Akiya F, Gregory MC (1986). Failure to visualize acutely injured kidneys with technetium-99m DMSA does not preclude recoverable function. J Nucl Med, 27(3), 377-9.
  47. Odell TW, Gregory MC (1995). Cost of hypertension treatment. J Gen Intern Med, 10(12), 686-8.
  48. GREGORY MC, ROBINSON JR (1965). EFFECTS OF UREA UPON THE WATER AND IONIC CONTENT OF LIVER SLICES. J Physiol, 177, 122-32.
  49. Kashtan CE, Atkin CL, Gregory MC, Michael AF (1989). Identification of variant Alport phenotypes using an Alport-specific antibody probe. Kidney Int, 36(4), 669-74.
  50. Zhou J, Gregory MC, Hertz JM, Barker DF, Atkin C, Spencer ES, Tryggvason K (1993). Mutations in the codon for a conserved arginine-1563 in the COL4A5 collagen gene in Alport syndrome. Kidney Int, 43(3), 722-9.
  51. Gregory MC, Hammond ME, Brewer ED (1988). Renal deposition of cytomegalovirus antigen in immunoglobulin-A nephropathy. Lancet, 1(8575-6), 11-4.
  52. Gregory MC, Mansell MA (1983). Pregnancy and cystinuria. Lancet, 2(8360), 1158-60.
  53. Merchant SN, B urgess B J, Adams JC, Kashtan CE, Gregory MC, Santi PA, Colvin R: Colns B, Nadol JB Jr (2004). Temporal bone histopathology in Alport syndrome. Laryngoscope, 114(9), 1609-18.
  54. Gross O, Borza DB, Anders HJ, Licht C, Weber M, Segerer S, Torra R, Gubler MC, Heidet L, Harvey S, Cosgrove D, Lees G, Kashtan C, Gregory M, Savige J, Ding J, Thorner P, Abrahamson DR, Antignac C, Tryggvason K, Hudson B, Miner JH (2009). Stem cell therapy for Alport syndrome: the hope beyond the hype. Nephrol Dial Transplant, 24(3), 731-4.
  55. Gross O, Borza D-B, Anders H-J, Licht C, Weber M, Segerer S, Torra R, Gubler M-C, Heidet L, Harvey S, Cosgrove D, Lees G, Kashtan C, Gregory M, Savige J, Ding J, Thorner P, Abrahamson DR, Antignac C,Tryggvason K, Hudson B, Miner JH (2009). Stem cell therapy for Alport syndrome: the hope beyond the hype*. Nephrol Dial Transplant, 24, 731-734.
  56. Flanigan KM, Bromberg MB, Gregory M, Baringer JR, Jones CR, Nester TA, Klatt EC, Townsend JJ (1998). Calciphylaxis mimicking dermatomyositis: ischemic myopathy complicating renal failure. Neurology, 51(6), 1634-40.
  57. Gregory MC (2005). The clinical features of thin basement membrane nephropathy. Semin Nephrol, 25(3), 140-5.
  58. Pokroy N, Ress S, Gregory MC (1977). Clofibrate-induced complications in renal disease: a case report. S Afr Med J, 52(20), 806-8.
  59. Jacobs P, Wormald LA, Gregory MC (1979). Absorption of iron polymaltose and ferrous sulphate in rats and humans. A comparative study. S Afr Med J, 55(26), 1065-72.
  60. Cassidy M, Gregory MC, Harley EH (1980). Primary overproduction of urate caused by a partial deficiency of hypoxanthine-guanine phosphoribosyl transferase. S Afr Med J, 57(23), 948-50.
  61. Barker DF, Hostikka SL, Zhou J, Chow LT, Oliphant AR, Gerken SC, Gregory MC, Skolnick MH, Atkin CL, Tryggvason K (1990). Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science, 248(4960), 1224-7.
  62. Cheung AK, Gregory MC (1985). Subclavian vein thrombosis in hemodialysis patients. Trans Am Soc Artif Intern Organs, 31, 131-5.
  63. Myers HS, Gregory M, Beighton P (1979). Renal failure in a 44-year-old female. Urol Radiol, 1(4), 251-3.
  64. Ekins BR, Rollins DE, Duffy DP, Gregory MC (1985). Standardized treatment of severe methanol poisoning with ethanol and hemodialysis. West J Med, 142(3), 337-40.
  65. Sprung RF, Cataldo RM, Gregory MC, Marks ML, Bull DA, Litwin SE (1996). Ruptured sinus of Valsalva aneurysm in a patient with autosomal dominant polycystic kidney disease. West J Med, 165(6), 379-82.
  66. Sasaki S, Zhou B, Fan WW, Kim Y, Barker DF, Denison JC, Atkin CL, Gregory MC, Zhou J, Segal Y, Sado Y, Ninomiya Y, Michael AF, Kashtan CE (1998). Expression of mRNA for type IV collagen alpha1, alpha5 and alpha6 chains by cultured dermal fibroblasts from patients with X-linked Alport syndrome. Matrix Biol, 17(4), 279-91.
  67. Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, Mari F, Hilbert P, Plevova P, Byers P, Cerkauskaite A, Gregory M, Cerkauskiene R, Ljubanovic DG, Becherucci F, Errichiello C, Massella L, Aiello V, Lennon R, Hopkinson L, Koziell A, Lungu A, Rothe HM, Hoefele J, Zacchia M, Martic TN, Gupta A, van Eerde A, Gear S, Landini S, Palazzo V, Al-Rabadi L, Claes K, Corveleyn A, Van Hoof E, van Geel M, Williams M, Ashton E, Belge H, Ars E, Bierzynska A, Gangemi C, Lipska-Zi'tkiewicz BS (2021). Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. Eur J Hum Genet, 29(8), 1186-1197.
  68. Florell SR, Egan CA, Gregory MC, Zone JJ, Petersen MJ (2001). Eosinophilic fasciitis occurring four weeks after the onset of dialysis in a renal failure patient. J Cutan Med Surg, 5(1), 33-6.
  69. Pont-Kingdon G, Sumner K, Gedge F, Miller C, Denison J, Gregory M, Lyon E (2009). Molecular testing for adult type Alport syndrome. BMC Nephrol, 10, 38.
  70. Pont-Kingdon G, Sumner K, Gedge F, Miller C, Denison J, Gregory M, Lyon E (2009). Molecular testing for adult type Alport syndrome. BMC Nephrol, 10, 38.
  71. Haas LJ, Gregory M (2000). Teaching behavior change skills to first-year medical students: a small group experiential approach. Education for health (Abingdon, England), 13(3), 337-45.
  72. Ahmed F, Kamae KK, Jones DJ, Deangelis MM, Hageman GS, Gregory MC, Bernstein P (2013). Temporal macular thinning associated with X-linked Alport syndrome. JAMA ophthalmology, 131(6), 777-82.
  73. Savige J, Lipska-Zietkiewicz BS, Watson E, Hertz JM, Deltas C, Mari F, Hilbert P, Plevova P, Byers P, Cerkauskaite A, Gregory M, Cerkauskiene R, Ljubanovic DG, Becherucci F, Errichiello C, Massella L, Aiello V, Lennon R, Hopkinson L, Koziell A, Lungu A, Rothe HM, Hoefele J, Zacchia M, Martic TN, Gupta A, van Eerde A, Gear S, Landini S, Palazzo V, Al-Rabadi L, Claes K, Corveleyn A, Van Hoof E, van Geel M, Williams M, Ashton E, Belge H, Ars E, Bierzynska A, Gangemi C, Renieri A, Storey H, Flinter (2022). Guidelines for Genetic Testing and Management of Alport Syndrome. Clinical journal of the American Society of Nephrology, 17(1), 143-154.
  74. Alverson DC, Saiki SM Jr, Caudell TP, Goldsmith T, Stevens S, Saland L, Colleran K, Brandt J, Danielson L, Cerilli L, Harris A, Gregory MC, Stewart R, Norenberg J, Shuster G, Panaoitis, Holten J 3rd, Vergera VM, Sherstyuk A, Kihmm K, Lui J, Wang K (2006). Reification of abstract concepts to improve comprehension using interactive virtual environments and a knowledge-based design: a renal physiology model. Studies in health technology and informatics, 119, 13-8.
  75. Zehnder AF, Adams JC, Santi PA, Kristiansen AG, Wacharasindhu C, Mann S, Kalluri R, Gregory MC, Kashtan CE, Merchant S (2005). Distribution of type IV collagen in the cochlea in Alport syndrome. Archives of otolaryngology--head & neck surgery, 131(11), 1007-13.
  76. Merchant SN, Burgess BJ, Adams JC, Kashtan CE, Gregory MC, Santi PA, Colvin R, Collins B, Nadol JB J (2004). Temporal bone histopathology in alport syndrome. The Laryngoscope, 114(9), 1609-18.
  77. Ibrahim A, Lin E, Hinckley M, Khalighi M, Altawallbeh Z, Al-Rabadi D, Al-Hassanat Z, Pezzolesi MG, Gregory MC, Al-Rabadi (2025). Renal Phenotype Variations Among Families with Autosomal Alport Syndrome: Potential Role of Modifier Genes. Kidney360,
  78. Ibrahim A, Altawallbeh Z, Revelo MP, Gregory M, Al-Rabadi (2024). Ocular Coherence Tomography Unveils Alport Syndrome: A Critical Tool in Detecting Collagen IV Nephropathies. Case reports in nephrology, 2024, 5087883.

Review

  1. Gregory MC, Shettigar UR, Kolff W (1984). Theoretical Value of Cascade plasmapheresis. 5, 517-529.
  2. Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter (2013). Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. Journal of the American Society of Nephrology, 24(3), 364-75.

Book Chapter

  1. Shettigar UR, Gregory MC, Kolff WJ (1987). Mathematical analysis of renal disease progression. In Andrade JD, Brophy JJ, Detmer DE, et al (Eds.), Artif Organs (pp. 279-291). New York: VCH publishers.
  2. Gregory MD, Strong M (2005). Manifestations and Pathophysiology. 1095-1141.
  3. Gregory M (2005). Alport's Syndrome and Related Disorders. 363-367.
  4. Gregory MC, Shamshirsam A, Kamgar M, Bekhernia M (2007). Alport's Syndrome, Fabry's Disease, and Nail-Patella Syndrome. 540-569.
  5. Alverson DC, Saiki SM Jr, Caudell TP, Goldsmith T, Stevens S, Saland L, Colleran K, Brandt J, Danielson L, Cerilli L, Harris A, Gregory MC, Stewart R, Norenberg J, Shuster G, Panaoitis, Holten J 3rd, Vergera VM, Sherstyuk A, Kihmm K, Lui J, Wang K (2006). Reification of Abstract Concepts to Improve Comprehension Using Interactive Virtual Environments and a Knowledge-based Design: A Renal Physiology Model. 13-18.
  6. Fraser AK, Gregory MC, Rose GA, Samuell C (1985). A study of factors affecting urinary citrate levels. 249-252.
  7. Gregory, M (2009). Alport's Syndrome and Related Disorders. 358-363.
  8. Gregory M (1997). Alport's Syndrome and Related Disorders. 318-323.
  9. Gregory M (2001). Alport's Syndrome. 589-619.
  10. Gregory MC, Atkin C (1993). Alport Syndrome. 571-591.
  11. Gregory M (1992). Alport's Syndrome and related hereditary nephritides. 143-156.
  12. Gregory MC, Morgan S (1994). Fabry's Disease. 206-210.
  13. Gregory M (1994). Alport's Syndrome and Related Disorders. 211-212.
  14. Barker DF, Atkin CL, Fain PR, Gregory M (1996). Clinical genetics and linkage markers in diagnosis of Alport Syndrome. 117, 29-45.
  15. Gregory MC, Terreros DA, Barker DF, Fain PR, Atkin C (1996). Alport syndrome--clinical phenotypes, incidence, and pathology. 117, 1-28.
  16. Gregory M (1978). Acid-base regulation. 28-32.
  17. Atkin CL, Gregory MC, Border W (1988). Alport Syndrome. 617-641.
  18. Gregory MC, Border WA, Atkin C (1988). Hereditary nephropathies. 791-793.
  19. Gregory M (1988). Artificial Kidney. 3, 1695-1712.
  20. Gregory MC, Atkin C (1992). Hereditary nephropathies. 736-738.
  21. Gregory MC, Tolman K (2000). Diseases: Manifestations and Pathophysiology. 1053-1097.
  22. Gregory M (2001). Urinalysis. 326-336.
  23. Gregory M (2001). Renal Function Tests. 319-325.
  24. Gregory M (2001). Alport's Syndrome and Related Disorders. 308-312.
  25. Gregory MC, Atkin C (1997). Alport's Syndrome, Fabry's Disease, and Nail-Patella Syndrome. 561-590.
  26. Gregory M (1997). Alport's Syndrome. 107-108.
  27. Gregory MC, Atkin C (1997). Hereditary nephropathies. 1018-1020.
  28. Gregory, M (2014). Alport Syndrome and Related Disorders. 375-380.
  29. Gregory, Martin C; Ibraham, Abdelrahman; Al-Rabadi, Laith Farra Collagenopathies: Alport syndrome and related disorders.

Conference Proceedings

  1. Davies-Jones GAB, Gregory MC, Whitty CW (1973). Permanent sequelae in the migraine attack. 5, 25-27.

Editorial

  1. Gregory MC (2004). Alport syndrome and thin basement membrane nephropathy: unraveling the tangled strands of type IV collagen. Kidney Int, 65(3), 1109-10.

Letter

  1. Solez K, Daugirdas J, Gregory MC, Frohnert PP, Bhowmik DM, Jha V, Cosyns JP (2001). Is "Chinese herbs nephropathy" a prejudicial term? [Letter to the editor]. Am J Kidney Dis, 38(5), 1141-2.
  2. Kinniburgh DW, Ash KO, Gregory MC (1983). Should routine microscopic examination of urine be discontinued? [Letter to the editor]. Clin Chem, 29(1), 212-3.
  3. Gottheiner TI, Pokroy N, Gregory MC (1977). Herpes zoster with bladder involvement. [Letter to the editor]. Lancet, 1(8010), 551.
  4. Gregory MC (1985). Comparing US and other homicide rates. [Letter to the editor]. West J Med, 143(3), 389-90.

Other

  1. Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, Mari F, Hilbert P, Plevova P, Byers P, Cerkauskaite A, Gregory M, Cerkauskiene R, Ljubanovic DG, Becherucci F, Errichiello C, Massella L, Aiello V, Lennon R, Hopkinson L, Koziell A, Lungu A, Rothe HM, Hoefele J, Zacchia M, Martic TN, Gupta A, van Eerde A, Gear S, Landini S, Palazzo V, Al-Rabadi L, Claes K, Corveleyn A, Van Hoof E, van Geel M, Williams M, Ashton E, Belge H, Ars E, Bierzynska A, Gangemi C, Lipska-Zi'tkiewicz B (2023). Correction: Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. European journal of human genetics,